We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AmerisourceBergen (ABC) Beats on Q4 Earnings, Issues '19 View
Read MoreHide Full Article
Maintaining the streak of positive earnings surprises, AmerisourceBergen Corporation posted adjusted earnings of $1.45 per share in the fourth quarter of fiscal 2018, beating the Zacks Consensus Estimate of $1.44 and improving 9% year over year.
The upside can be attributed to strong growth in the Pharmaceutical Distribution segment and the World Courier business.
Revenues improved almost 10.7% to $43.29 billion in the reported quarter. The figure missed the Zacks Consensus Estimate of $43.53 billion.
The stock has a Zacks Rank #3 (Hold).
Fiscal 2018 Results at a Glance
AmerisourceBergen registered revenues of $167.9 billion in fiscal 2018. This figure lagged the Zacks Consensus Estimate of $168.10 billion. The Pharmaceutical Distribution Services contributed to 96.3% of net revenues in fiscal 2018. The other segment accounted for 3.7% of net revenues.
Adjusted earnings came in at $6.49, surpassing the Zacks Consensus Estimate of $6.48.
Revenues in the segment were $41.73 billion, up 10.8% on a year-over-year basis. Operating income was $357 million, down 10.7% year over year.
Pharmaceutical Distribution witnessed favorable results in the quarter, courtesy of solid expansion in revenues and gross profit, the acquisition of H.D. Smith and especially strong oncology product sales.
However, lower sales in the PharMEDium segment partially offset operating income.
Other Segment
This segment includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI Veterinary Supply.
Revenues in the segment came in at $1.60 billion, up 7.9% year over year. Growth in the segment was driven by consolidation of the specialty joint venture in Brazil and revenues from MWI, ABCS's growth in Canadian operations and World Courier business.
Operating income in the segment was $75 million in the quarter, up 5.2% year over year. Lackluster performance in the ABCS’s Lash Group partially offset operating income in the segment.
Margin Analysis
In the quarter under review, AmerisourceBergen registered gross profit of $1.03 billion, down 11.9% on a year-over-year basis. As a percentage of revenues, gross margin was 2.4%, down 60 basis points (bps) from the prior-year quarter's tally.
AmerisourceBergen registered operating income of $154.1 million.
However, deducting distribution, selling and administrative expenses from gross profit, AmerisourceBergen registered adjusted operating income of $374.8 million, i.e. 0.9% of net revenues. This compares with 1.6% registered in the year-ago quarter. Thus, adjusted operating margin declined 70 bps year over year.
Guidance
Management expects revenue growth in the mid-single digit percent range for fiscal 2019. The Zacks Consensus Estimate is currently pegged at $179.83 billion.
Adjusted earnings per share (EPS) is expected in the range of $6.65-$6.95. The Zacks Consensus Estimate is currently pegged at $6.48, which is below the guidance.
Intuitive Surgical reported third-quarter 2018 adjusted EPS of $2.83, which beat the Zacks Consensus Estimate of $2.65. Revenues totaled $920.9 million, also surpassing the consensus estimate of $918.6 million.
Stryker posted third-quarter 2018 adjusted EPS of $1.69, beating the Zacks Consensus Estimate by a penny. Operating margin was 17.8%, up 30 bps.
Merit Medical reported third-quarter 2018 adjusted EPS of 47 cents, which trumped the Zacks Consensus Estimate of 42 cents. Revenues of $221.6 million edged past the consensus estimate of $218 million.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
AmerisourceBergen (ABC) Beats on Q4 Earnings, Issues '19 View
Maintaining the streak of positive earnings surprises, AmerisourceBergen Corporation posted adjusted earnings of $1.45 per share in the fourth quarter of fiscal 2018, beating the Zacks Consensus Estimate of $1.44 and improving 9% year over year.
The upside can be attributed to strong growth in the Pharmaceutical Distribution segment and the World Courier business.
Revenues improved almost 10.7% to $43.29 billion in the reported quarter. The figure missed the Zacks Consensus Estimate of $43.53 billion.
The stock has a Zacks Rank #3 (Hold).
Fiscal 2018 Results at a Glance
AmerisourceBergen registered revenues of $167.9 billion in fiscal 2018. This figure lagged the Zacks Consensus Estimate of $168.10 billion. The Pharmaceutical Distribution Services contributed to 96.3% of net revenues in fiscal 2018. The other segment accounted for 3.7% of net revenues.
Adjusted earnings came in at $6.49, surpassing the Zacks Consensus Estimate of $6.48.
AmerisourceBergen Corporation Price and Consensus
AmerisourceBergen Corporation Price and Consensus | AmerisourceBergen Corporation Quote
Segmental Analysis
Pharmaceutical Distribution Segment
Revenues in the segment were $41.73 billion, up 10.8% on a year-over-year basis. Operating income was $357 million, down 10.7% year over year.
Pharmaceutical Distribution witnessed favorable results in the quarter, courtesy of solid expansion in revenues and gross profit, the acquisition of H.D. Smith and especially strong oncology product sales.
However, lower sales in the PharMEDium segment partially offset operating income.
Other Segment
This segment includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI Veterinary Supply.
Revenues in the segment came in at $1.60 billion, up 7.9% year over year. Growth in the segment was driven by consolidation of the specialty joint venture in Brazil and revenues from MWI, ABCS's growth in Canadian operations and World Courier business.
Operating income in the segment was $75 million in the quarter, up 5.2% year over year. Lackluster performance in the ABCS’s Lash Group partially offset operating income in the segment.
Margin Analysis
In the quarter under review, AmerisourceBergen registered gross profit of $1.03 billion, down 11.9% on a year-over-year basis. As a percentage of revenues, gross margin was 2.4%, down 60 basis points (bps) from the prior-year quarter's tally.
AmerisourceBergen registered operating income of $154.1 million.
However, deducting distribution, selling and administrative expenses from gross profit, AmerisourceBergen registered adjusted operating income of $374.8 million, i.e. 0.9% of net revenues. This compares with 1.6% registered in the year-ago quarter. Thus, adjusted operating margin declined 70 bps year over year.
Guidance
Management expects revenue growth in the mid-single digit percent range for fiscal 2019. The Zacks Consensus Estimate is currently pegged at $179.83 billion.
Adjusted earnings per share (EPS) is expected in the range of $6.65-$6.95. The Zacks Consensus Estimate is currently pegged at $6.48, which is below the guidance.
Earnings of Other MedTech Majors at a Glance
A few better-ranked stocks in the broader medical space which also reported solid earnings this season are Intuitive Surgical (ISRG - Free Report) , Stryker Corporation (SYK - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) . Each of the stocks carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Intuitive Surgical reported third-quarter 2018 adjusted EPS of $2.83, which beat the Zacks Consensus Estimate of $2.65. Revenues totaled $920.9 million, also surpassing the consensus estimate of $918.6 million.
Stryker posted third-quarter 2018 adjusted EPS of $1.69, beating the Zacks Consensus Estimate by a penny. Operating margin was 17.8%, up 30 bps.
Merit Medical reported third-quarter 2018 adjusted EPS of 47 cents, which trumped the Zacks Consensus Estimate of 42 cents. Revenues of $221.6 million edged past the consensus estimate of $218 million.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>